Clinical Study on Inaticabtagene Autoleucel (Inati-cel; CNCT19) Injection for Adolescents and Adults With B-Cell Acute Lymphoblastic Leukemia in First Complete Remission (CR1)
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Inaticabtagene autoleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms JUVENTAS-ALL05
- 22 Jan 2025 New trial record